Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Prepaid Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Prepaid Assets for 10 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 52.5% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.0 million through Dec 2025, up 52.5% year-over-year, with the annual reading at $61.0 million for FY2025, 52.5% up from the prior year.
  • Prepaid Assets for Q4 2025 was $61.0 million at Ultragenyx Pharmaceutical, up from $53.2 million in the prior quarter.
  • The five-year high for Prepaid Assets was $77.5 million in Q2 2022, with the low at $40.0 million in Q4 2024.
  • Average Prepaid Assets over 5 years is $59.2 million, with a median of $61.1 million recorded in 2025.
  • The sharpest move saw Prepaid Assets tumbled 35.15% in 2023, then skyrocketed 52.5% in 2025.
  • Over 5 years, Prepaid Assets stood at $71.7 million in 2021, then fell by 3.93% to $68.9 million in 2022, then tumbled by 30.92% to $47.6 million in 2023, then fell by 15.99% to $40.0 million in 2024, then skyrocketed by 52.5% to $61.0 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $61.0 million, $53.2 million, and $61.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.